The capacity to upregulate the degranulation-related surface antigen CD107a in response to K562-cell mediated activation did not show similar significant differences between healthy individuals, untreated AML patients and patients after chemotherapy, but seemed to be somewhat increased after HDC plus IL-2 treatment (Figure 6A, upper right panel). Here, LAMP1 is linked to acute myeloid leukemia.